CMS Takes Steps to Ensure Medicare Beneficiaries Have Wide Access to COVID-19 Antibody Treatment

CMS Takes Steps to Ensure Medicare Beneficiaries Have Wide Access to COVID-19 Antibody Treatment   The Centers for Medicare & Medicaid Services announced that starting Tuesday, November 10, 2020, Medicare beneficiaries can receive coverage of monoclonal antibodies to treat coronavirus disease 2019 (COVID-19) with no cost-sharing during the public health emergency (PHE). CMS’ coverage of monoclonal antibody infusions applies to bamlanivimab, which received an emergency use authorization (EUA) from the U.S. Food and Drug Administration on Tuesday, November 10. Full press release

Centers for Medicare & Medicaid Services (CMS) has sent this Center for Medicare and Medicaid Innovation (CMMI) Update. To contact Centers for Medicare & Medicaid Services (CMS) go to our contact us page.